【资料】肿瘤细胞疫苗综述 On the road to a tumor cell vaccine
这个帖子发布于 20 年零 262 天前，其中的信息可能已发生改变或有所发展。
文章发表杂志的IF不高，作者直接了近年来肿瘤细胞疫苗的概况。
细胞免疫治疗最早开展于80年代，以LAK (lymphokine-activated killer cells) 细胞治疗和TIL (tumor-infiltrating lymphocytes) 为代表。TIL在黑色素瘤的临床治疗显示了一定的疗效。通过TIL鉴定得到的一些肿瘤抗原已被应用于构建新的肿瘤疫苗。文章综述了过去的近20年里，从LAK细胞到最近的DC细胞免疫治疗的研究状况。
Cellular immunotherapy (CI), as we now know it, began in the early 1980s with the use of lymphokine-activated killer cells (LAK) and progressed to the use of the immunologically specific, tumor-infiltrating lymphocytes (TIL). TIL were shown to be particularly effective against melanoma and it was in these trials that we learned the importance of immunologic specificity for tumor. With the identification and characterization of tumor antigens recognized by TIL, we now see the use of these antigens in various forms constituting vaccines. Investigators are using tumor antigens alone or in combination with dendritic cells (DCs), the body’s most efficient and powerful antigen-presenting cell. Therapies are being delivered to many patients with different types of cancer in order to combat bulky disease, eliminate micro-metastatic disease, and provide a memory mechanism to fight tumor recurrence. This review will detail the past 18 years and present the developments that have been made in this therapy. Many believe that with continued development, immunotherapy will provide a fourth modality of cancer therapy.
细胞免疫治疗最早开展于80年代，以LAK (lymphokine-activated killer cells) 细胞治疗和TIL (tumor-infiltrating lymphocytes) 为代表。TIL在黑色素瘤的临床治疗显示了一定的疗效。通过TIL鉴定得到的一些肿瘤抗原已被应用于构建新的肿瘤疫苗。文章综述了过去的近20年里，从LAK细胞到最近的DC细胞免疫治疗的研究状况。
Cellular immunotherapy (CI), as we now know it, began in the early 1980s with the use of lymphokine-activated killer cells (LAK) and progressed to the use of the immunologically specific, tumor-infiltrating lymphocytes (TIL). TIL were shown to be particularly effective against melanoma and it was in these trials that we learned the importance of immunologic specificity for tumor. With the identification and characterization of tumor antigens recognized by TIL, we now see the use of these antigens in various forms constituting vaccines. Investigators are using tumor antigens alone or in combination with dendritic cells (DCs), the body’s most efficient and powerful antigen-presenting cell. Therapies are being delivered to many patients with different types of cancer in order to combat bulky disease, eliminate micro-metastatic disease, and provide a memory mechanism to fight tumor recurrence. This review will detail the past 18 years and present the developments that have been made in this therapy. Many believe that with continued development, immunotherapy will provide a fourth modality of cancer therapy.
